In a small case series, all eyes in infants treated with bevacizumab (Avastin, Genentech) for retinopathy of prematurity (ROP) showed a decrease in fluorescein leakage from neovascularization after the injection. Although this series involved only five eyes in three patients with short-term follow-up, the results suggest that bevacizumab could be an alternative for treatment of severe ROP that is refractive to conventional laser treatment, said Shunji Kusaka, MD, Department of Ophthalmology, Osaka University Medical School, Suita, Japan.
In a small case series, all eyes in infants treated with bevacizumab (Avastin, Genentech) forretinopathy of prematurity (ROP) showed a decrease in fluorescein leakage from neovascularizationafter the injection. Although this series involved only five eyes in three patients with short-termfollow-up, the results suggest that bevacizumab could be an alternative for treatment of severe ROPthat is refractive to conventional laser treatment, said Shunji Kusaka, MD, Department ofOphthalmology, Osaka University Medical School, Suita, Japan.
The patients had zone 1 ROP, had developed partial retinal detachments, and were consideredunresponsive to treatment. Gestational age ranged from 24 to 26 weeks and birth weight from 700 to962 g. Under general anesthesia, the patients were given intravitreal injections of 0.5 to 0.75 mg ofbevacizumab. The drug was administered following vitrectomy in two patients and was the soletreatment in three patients.
"In each eye, fluorescein angiography showed that vascular activity was reduced and the retina wassuccessfully re-attached," Dr. Kusaka said. However, one eye progressed from Stage 3 to Stage 4ROP.
Dr. Kusaka said that he would like to test this therapy in patients with earlier stages of ROP.However, one of the safety concerns that must be addressed in future studies is the drug's effect onphysiological vessel growth, In addition, functional tests should be performed; none were conductedin this series.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
July 30th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction